ACM
BBOT

ADAR1 Capital Management’s BridgeBio Oncology BBOT Stock Holding History

ADAR1 Capital Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-226,248
Closed -$2.83M – 345
2025
Q4 		$2.83M Sell
226,248
-274,980
-55% -$3.33M 0.21% 85
2025
Q3 		$5.8M Buy
501,228
+58,613
+13% +$611K 0.55% 44
2025
Q2 		$4.7M Sell
442,615
-27,114
-6% -$293K 0.72% 35
2025
Q1 		$5.31M Buy
469,729
+65,591
+16% +$705K 0.99% 30
2024
Q4 		$4.24M Hold
404,138
– – 0.85% 30
2024
Q3 		$4.22M Hold
404,138
– – 0.69% 30
2024
Q2 		$4.13M Buy
404,138
+638
+0.2% +$6.57K 0.78% 24
2024
Q1 		$4.2M Buy
+403,500
New +$4.18M 0.95% 18

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management's BBOT Position: Q1 2026 in Review

ADAR1 Capital Management sold out of BridgeBio Oncology (BBOT) in Q1 2026, closing a stake of 226,248 shares — an estimated $2.83M sold.

ADAR1 Capital Management first reported a position in BBOT in Q1 2024 and held it in 8 quarters. The position peaked at $5.8M in Q3 2025. 67 funds tracked by Wall St. Rank hold BBOT as of Q1 2026.

  • ADAR1 Capital Management reported no remaining BridgeBio Oncology position as of Q1 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 226,248 BridgeBio Oncology shares in Q1 2026, an estimated $2.83M.
  • ADAR1 Capital Management first reported a position in BridgeBio Oncology in Q1 2024 and held it in 8 quarters.
  • ADAR1 Capital Management's BridgeBio Oncology position peaked at $5.8M in Q3 2025.
  • 67 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.